Jubilant Ingrevia Ltd., incorporated in the year 2019, is a Small Cap company (having a market cap of Rs 9665.98 Crore) operating in Chemicals sector.

Buy Jubilant Ingrevia, target price Rs 735: Anand Rathi

Jubilant Ingrevia tumbled 4.19% to Rs 562.05 after the company reported 15.36% decline in consolidated net profit to Rs 48.74 crore in Q1 FY25 compared with net profit of Rs 57.59 crore in Q1 FY24.

Spotlight

Jubilant Ingrevia slips after Q1 PAT slides 15% YoY to Rs 48 cr in FY25

Jubilant Ingrevia reported 15.36% decline in consolidated net profit to Rs 48.74 crore in Q1 FY25 compared with net profit of Rs 57.59 crore in Q1 FY24.

Jubilant Ingrevia Q1 PAT slides 15% YoY to Rs 48 cr in FY25

Earnings

Jubilant Ingrevia consolidated net profit declines 15.37% in the June 2024 quarter

Upcoming results: Alok Industries, Bajaj Auto, Century Textiles & Industries, Crisil, Himadri Speciality Chemical, Jubilant Ingrevia, Just Dial and L&T Finance

Stock Alert: Jio Financial Services, Spicejet, Hatsun Agro Product, Hindustan Unilever (HUL)

Jubilant Ingrevia Ltd clocked volume of 85.85 lakh shares by 14:14 IST on NSE, a 37.32 times surge over two-week average daily volume of 2.30 lakh shares

Volumes soar at Jubilant Ingrevia Ltd counter

Mangalore Refinery And Petrochemicals Ltd, L T Foods Ltd, Jubilant Ingrevia Ltd and Chennai Petroleum Corporation Ltd are among the other gainers in the BSE’s ‘A’ group today, 09 July 2024.

Bombay Burmah Trading Corporation Ltd leads gainers in ‘A’ group

Jubilant Ingrevia: The market capitalisation of Jubilant Ingrevia is Rs 8,383.76 crore, according to Bombay Stock Exchange (BSE)

Jubilant Ingrevia up 2% USFDA issues Zero observations for Bharuch unit

Jubilant Ingrevia said that it has received Establishment Inspection Report (EIR) with ‘zero’ Form 483 inspectional observations from the United States Food and Drug Administration (US FDA).

Jubilant Ingrevia gets EIR for Bharuch facility from US FDA

Jubilant Ingrevia stock surges 7% above 200-Day Moving Average, indicating bullish case. Traders can go long now, accumulate on dips, and target ₹540-545 over next 3-4 weeks. Keep stop-loss at ₹440, trail up to ₹485 & ₹510. Exit long positions at ₹535. Risk of loss in trading.

Stock to buy today: Jubilant Ingrevia (₹476.15)

Khubchandani, in his most recent role, has served as Co-CEO and Whole-time Director of Jubilant Ingrevia. Over his 20-year career at Jubilant Ingrevia, Khubchandani was a strategic business leader, developed high-performing teams, and oversaw solutions and offerings for pharmaceutical, agrochemical,…

PAG-led Sekhmet Pharmaventures announces the hiring of Anil Khubchandani as MD and CEO

Hasn't fared well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Financials growth has been moderate for a few years

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Jubilant Ingrevia is engaged in the business of integrated life science products.